Eugene Schneider - 15 Jan 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP, Chf Clinical Develop Offc
Issuer ticker: IONS
Reported as of: 15 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Jan 2022, 18:45:07 UTC
Prior SEC filing: 05 Jan 2022
Next SEC filing: 20 Jan 2022
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider

Key filing fact

Eugene Schneider filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 19 Jan 2022.

Key facts

This page summarizes Eugene Schneider's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Jan 2022, 18:45.

Change

Previous filing in this sequence was filed on 05 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Performance Restricted Stock Units

Award

Transaction value: $0
Shares: +12,099
Change %
Price: $0.000000
Shares after: 12,099
Date: 15 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,099
Exercise price: $0.000000
Footnotes: F1, F2

IONS transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +16,133
Change %: +53%
Price: $0.000000
Shares after: 46,725
Date: 15 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,133
Exercise price: $0.000000
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Footnote F2

Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

Footnote F3

Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Footnote F4

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Footnote F5

Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.